Although there are no studies reporting the different mechanisms of action of ruxolitinib treatment depending on various molecular subtypes of breast cancer, Escher et al. report that the treatment effect of ruxolitinib could be affected by the ER expression status of breast cancer cells [43]. This evidence concerns the gene ESR1 and breast cancer.